However, PET imaging has not been used for characterization of changes in tumor metabolism resulting from orlistat-induced inhibition of FASN due to uncertainty of pharmacodynamic changes in metabolic pools and signal transduction pathways that could serve as biomarkers of treatment response. This evidence concerns the gene FASN and neoplasm.